Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03148314
Other study ID # VMIS
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 1, 2017
Est. completion date June 1, 2018

Study information

Verified date April 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The world health organization defined abortion or miscarriage as : the expulsion or extraction from its mother of a fetus or an embryo weighting 500 grams or less ,or any other wise product of gestation of any weight irrespective of gestational age and weather or not there is evidence of life and weather or not the abortion was spontaneous or induced Miscarriage is the most common complication of pregnancy occurring in 10-20% of clinically recognized pregnancies (Bag. It is estimated that around 40% of early pregnancies result in miscarriage. A large majority of those are lost before the menstrual period is missed. More than 80%of abortions occur in first 12 weeks of pregnancy, and the rate decrease there after For clinical purposes: abortion is subdivided into: threatened abortion, inevitable abortion, incomplete abortion ,missed abortion ,septic abortion ,and recurrent abortion


Recruitment information / eligibility

Status Completed
Enrollment 140
Est. completion date June 1, 2018
Est. primary completion date June 1, 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - single dead fetus up-to 12 weeks. - no low lying placenta - no scarred uterus - no or mild bleeding - no evidence of infection - accepting to participate in the study. Exclusion Criteria: - Advanced hepatic diseases . - Suspected molar pregnancy - Ectopic pregnancy or pregnancy of unknown location - Haemodynamically unstable with significant anaemia ie Hb<10 - Uncontrolled severe asthma - Chronic adrenal failure - Known or suspected heart disease - Glaucoma - Haemoglobinopathies - Haemorrhagic disorders and anti-coagulation therapy (aspirin accepted) - Adrenal suppression and long term glucocorticoid therapy (may require corticosteroid) - Patient living in remote areas with difficulty in accessing hospital

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
vaginal misoprostol
(800µgm.x 2 doses 3 hours).
buccal/sublingual misoprostol
200 µgm.x4 hrs.x 6 doses

Locations

Country Name City State
Egypt Women Health Hospital - Assiut university Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with complete abortion (success rate). 1 week
Secondary Number of misoprostol doses 1 week
Secondary induction-abortion time 1 week
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04499976 - Isonicotinic Acid Hydrazide Pretreatment With Misoprostol Induction of Abortion in First-trimester Missed Miscarriage Phase 4
Active, not recruiting NCT03736681 - Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage Phase 1
Completed NCT03636451 - Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o Phase 3
Recruiting NCT05124314 - Comparison of Two Different Drug Regimens for Medical Treatment of Early Pregnancy Loss Phase 4
Recruiting NCT02917785 - Testing the Efficiency of Karman Curette in the Treatment of Misoprostol Failure in Women With Missed Abortion N/A
Completed NCT04906278 - Amniotomy for Second-trimester Pregnancy Termination N/A
Not yet recruiting NCT03799081 - Use of Fetoscopy in Missed Abortion N/A
Completed NCT00784797 - Misopristol Versus Pitocin for Second Trimester Abortion Phase 4
Completed NCT03767179 - Research of Serum Procalcitonin, ESR, CRP And Leukocyte Levels in Fertile Missed Abortion Cases
Completed NCT02515604 - Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure Phase 4
Completed NCT00410345 - Cervical Rippening With Antiprogesterone in Midtrimester Abortions Phase 4